[Modification of serum uric acid concentration under long-term therapy with the lipid-regulating drug Duolip].
During an 8-months treatment period the effect of Duolip on serum uric acid in 112 patients with hyperlipidemia was studied. In this open clinical trial a long-lasting hypouricemic effect could be shown for Duolip. This response was more pronounced with higher initial serum uric acid concentrations and could only be observed in patients with serum uric acid levels above 6.4 mg%. Thus, in one patient both risk factors of atherosclerosis--hyperlipidemia and hyperuricemia--can be treated by a single drug.
D002994:Clofibrate / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors; D014527:Uric Acid / Q000097:blood*
D000960:Hypolipidemic Agents; C028764:etofylline clofibrate; D014527:Uric Acid; D002994:Clofibrate
Beeinflussung der Serumharnsäure-Konzentration unter Langzeittherapie mit dem Lipidregulans Duolip.